Visceral Adiposity and Renal Health: From Pathophysiological Mechanisms to Novel Therapeutic Strategies. (PubMed, J Clin Med) - Sep 27, 2026 - "Obesity-related chronic kidney disease (ob-CKD) is an increasingly prevalent condition whose pathogenesis extends beyond excess body mass to the metabolic dysfunction of visceral adipose tissue (VAT)...The therapeutic landscape now includes agents with combined weight-loss and nephroprotective properties: glucagon-like peptide-1 (GLP-1) receptor agonists (FLOW trial), dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 agonists (tirzepatide), sodium-glucose co-transporter 2 inhibitors (SGLT2i), and non-steroidal mineralocorticoid receptor antagonists (finerenone), alongside metabolic surgery for refractory cases. This review provides an integrative framework for shifting clinical practice from BMI-centric to visceral adiposity-driven approaches in the prevention and management of ob-CKD."
Journal • Review • Chronic Kidney Disease • Genetic Disorders • Metabolic Disorders • Nephrology • Obesity • Oncology • Renal Disease • IL6 • LEP • TNFA
|
|
Alberto Ortiz; Ana Sánchez Horrillo; Beatriz Fernandez-Fernandez; Borja Quiroga; Clara Garcia-Carro; Enrique Morales; José Portolés; María A Bajo; Maria Jose Soler; María Marques Vidas
|